Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
87%
Perianal Crohn's Disease
28%
Tumour Necrosis Factor Inhibitor (TNFi)
25%
Ulcerative Colitis
23%
Magnetic Resonance Enterography
21%
Ustekinumab
20%
Adverse Event Reporting System
17%
Vedolizumab
16%
Adverse Events
16%
Fistula
16%
Computed Tomography
15%
Disease Activity
13%
Clinical Remission
13%
Small Bowel Crohn's Disease
13%
Chronic Inflammatory Diseases
13%
Confidence Interval
12%
Anti-tumor Necrosis Factor (anti-TNF)
12%
Non-alcoholic Fatty Liver Disease (NAFLD)
12%
Stricture
12%
Computed Tomography Enterography
12%
COVID-19
11%
Pouch
11%
Thiopurines
11%
Real-world Effectiveness
11%
Crohn's Disease of the Pouch
10%
Odds Ratio
10%
Monotherapy
10%
Remission
10%
Ischemic Colitis
9%
United States
9%
Immunomodulator
9%
Magnetic Resonance Imaging
9%
Tofacitinib
9%
Perianal Fistula
9%
Clinical Trials
9%
Crohn's Colitis
8%
Disease Severity
8%
Risk Factors
8%
Infliximab
8%
Medical Management
8%
Clinical Practice
8%
Endoscopic Remission
7%
Bariatric Surgery
7%
Medical Therapy
7%
Response to Therapy
7%
Small Intestine
7%
Ileal Pouch-anal Anastomosis
7%
Vaccination
7%
Inflammation
6%
Medicine and Dentistry
Crohn's Disease
90%
Inflammatory Bowel Disease
67%
Diseases
29%
Patient with Inflammatory Bowel Disease
28%
Fistula
23%
Patient with Crohn's Disease
22%
Ulcerative Colitis
22%
Magnetic Resonance Enterography
20%
Disease Activity
16%
Magnetic Resonance Imaging
15%
Computer Assisted Tomography
14%
Pouchitis
12%
Anal Fistula
11%
Combination Therapy
10%
Tumor Necrosis Factor
10%
Nonalcoholic Fatty Liver
9%
TNF Inhibitor
9%
Ileo-Anal Pouch
9%
Biological Marker
9%
Biological Product
9%
Computed Tomography Enterography
9%
Systematic Review
7%
Vedolizumab
7%
Cancer
7%
Fluorodeoxyglucose F 18
7%
Bariatric Surgery
7%
Patient-Reported Outcome
7%
Ustekinumab
7%
Adverse Event
7%
Stricture
7%
Disease Course
7%
Serositis
6%
Endoscopy
6%
Positron Emission Tomography-Computed Tomography
6%
Biological Therapy
6%
Clinical Trial
5%
Odds Ratio
5%
Dysplasia
5%
Disease Severity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
62%
Inflammatory Bowel Disease
56%
Adverse Event
36%
Tumor Necrosis Factor Inhibitor
32%
Remission
22%
Ulcerative Colitis
20%
Ustekinumab
16%
Tumor Necrosis Factor
15%
Diseases
13%
Mercaptopurine
11%
Biological Product
11%
Combination Therapy
11%
Immunomodulating Agent
10%
Vedolizumab
10%
Inflammatory Disease
9%
Monotherapy
9%
Tofacitinib
8%
Infection
7%
Infliximab
7%
Aminosalicylic Acid
7%
Messenger RNA
6%
Rheumatoid Arthritis
6%
Inflammatory Arthritis
6%
SARS Coronavirus
6%
Disease Activity
5%
Risankizumab
5%
Clinical Trial
5%
Biological Marker
5%
Fistula
5%